Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Final DREAMM-3 Phase 3 Findings: Belantamab Mafodotin Compared With Pomalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

  • By

  • Meletios Athanasios Dimopoulos

  • Vania Hungria

  • Haitao Meng

  • Atanas Radinoff

  • Jian Li

  • Sosana Delimpasi

  • Ting Niu

  • Gabor Mikala

  • Tamas Masszi

  • Marcelo Capra

  • Michael Low

  • Angelo Maiolino

  • Yan Xu

  • Xavier Leleu

  • Vasiliki Pappa

  • Dominik Chraniuk

  • Tatiana Konstantinova

  • Iurii Osipov

  • Shawn Hakim

  • Chris Brawley

  • Gabriela Tubel

  • Astrid McKeown

  • Julia Boyle

  • Sumita Roy-Ghanta

  • Katja Weisel

  • October 17, 2026

Share

Original Source(s)

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • by Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel

  • October 17, 2026

Related Content

Daily-life dynamics of general and cognitive fatigue in childhood cancer survivors: An experience sampling and wearable study

The association between MGMT expression and outcome in H3 G34-mutant diffuse hemispheric glioma is robust to adjustment for pre-analytic and technical variables

Weekly hippocampal diffusion changes during partial-brain radiation therapy for high-grade glioma: associations with dose and early memory change